ClinicalTrials.gg
CompletedNCT07305831Updated Apr 21, 2026

A Clinical Trial to Evaluate the Effect of Ulonivirine (MK-8507) on Heart Rhythm in Healthy Adults (MK-8507-012)

A Phase 1 interventional study of Ulonivirine and Moxifloxacin in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Researchers are looking for new treatments for HIV-1 (human immunodeficiency virus type 1) that are safe, well-tolerated, and can be taken less often. HIV-1 is the most common type of HIV, which is a virus that attacks cells of the immune system.

Ulonivirine (MK-8507) is a study medicine designed to treat HIV-1

The goal of this study is to learn if ulonivirine does not increase the QT interval (a measure of heart rhythm on an electrocardiogram) above a certain amount. Researchers also want to learn what happens to the amount of ulonivirine in a healthy person's body over time.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is in good health before randomization
  • Has (BMI) between 18 and 32 kg/m2, inclusive

Exclusion criteria

Exclusion Criteria:

  • Has a history of endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
  • Has history of cancer ()
  • Has positive test(s) for surface antigen (HBsAg), antibodies or (HIV)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Moxifloxacin 400 mg + Placebo (Arm 1)

    Participants will receive ulonivirine dose matched placebo + moxifloxacin dose matched placebo OR ulonivirine dose matched placebo + moxifloxacin 400 mg.

    Drug: Moxifloxacin · Drug: Ulonivirine Placebo · Drug: Moxifloxacin Placebo

  • Experimental
    Ulonivirine Dose 1 + Placebo (Arm 2)

    Participants will receive ulonivirine dose matched placebo + moxifloxacin dose matched placebo OR moxifloxacin dose matched placebo + ulonivirine Dose 1.

    Drug: Ulonivirine · Drug: Ulonivirine Placebo · Drug: Moxifloxacin Placebo

Interventions

  • Oral tablet

    Also known as: MK-8507, ULO

  • Oral tablet

  • DrugUlonivirine Placebo

    Oral tablet

  • DrugMoxifloxacin Placebo

    Oral tablet

06

What researchers measure

Primary outcomes

  1. Change From Baseline in QT Interval Corrected for Heart Rate (QTc) Following Ulonivirine Administration

    Change from baseline in QTc following ulonivirine administration will be reported.

    Time frame: Baseline and up to approximately 24 hours

  2. Plasma Concentration of Ulonivirine at QTc Intervals (Cqtc)

    Blood samples will be collected to determine the Cqtc of ulonivirine.

    Time frame: At designated timepoints (up to approximately 24 hours)

Secondary outcomes

  1. Change From Baseline in QT Interval Corrected for Heart Rate (QTc) Following Moxifloxacin Administration

    Change from baseline in QTc following moxifloxacin administration will be reported.

    Time frame: Baseline to up to approximately 24 hours

  2. Plasma concentration of Moxifloxacin at QTc intervals (Cqtc)

    Blood samples will be collected to determine the Cqtc of moxifloxacin.

    Time frame: At designated timepoints (up to approximately 24 hours)

  3. Maximum Plasma Concentration (Cmax) of Moxifloxacin

    Blood samples will be collected to determine the Cmax of moxifloxacin.

    Time frame: At designated timepoints (up to approximately 168 hours)

  4. Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC0-24) of Ulonivirine

    Blood samples will be collected to determine the AUC0-24 of ulonivirine.

    Time frame: At designated timepoints (up to 168 hours)

  5. Maximum Plasma Concentration (Cmax) of Ulonivirine

    Blood samples will be collected to determine the Cmax of ulonivirine.

    Time frame: At designated timepoints (up to 168 hours)

  6. Time to Maximum Plasma Concentration (Tmax) of Ulonivirine

    Blood samples will be collected to determine the Tmax of ulonivirine.

    Time frame: At designated timepoints (up to 168 hours)

07

Study locations

1 site
  • ICON Early Phase Services (0001)
    San Antonio, Texas 78209, United States
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2026 to primary completion in Apr 2026, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2025
First posted
Dec 26, 2025
StartActual
Jan 22, 2026
Primary completionActual
Apr 9, 2026
CompletionActual
Apr 9, 2026
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07305831
Responsible party
Sponsor
First posted
Dec 26, 2025
Start date
Jan 22, 2026
Primary completion
Apr 9, 2026
Completion
Apr 9, 2026
Last update
Apr 21, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ulonivirine · Moxifloxacin

Start the discussion